Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company's product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company's product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:DNDN
- CUSIP: 24823Q10
- Web: www.dendreon.com/
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.32
- P/E Growth: N/A
- Net Margins: -30.18%
- Return on Assets: -25.12%
Frequently Asked Questions for Dendreon (NASDAQ:DNDN)
What is Dendreon's stock symbol?
Dendreon trades on the NASDAQ under the ticker symbol "DNDN."
How were Dendreon's earnings last quarter?
Dendreon Co. (NASDAQ:DNDN) issued its quarterly earnings results on Monday, November, 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.04. The company had revenue of $73.10 million for the quarter, compared to analyst estimates of $78.72 million. The firm's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.44) EPS. View Dendreon's Earnings History.
Who are some of Dendreon's key competitors?
Some companies that are related to Dendreon include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), ProMetic Life Sciences (PLI), Theratechnologies (TH), Mirati Therapeutics (MRTX), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), Anavex Life Sciences Corp. (AVXL), VBI Vaccines (VBIV), XOMA Corporation (XOMA), Protalix Biotherapeutics (PLX), Concordia International Corp (CXR), ContraFect Corporation (CFRX), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF) and Can Fite Biopharma Ltd (CANF).
How do I buy Dendreon stock?
Shares of Dendreon can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dendreon's stock price today?
MarketBeat Community Rating for Dendreon (NASDAQ DNDN)MarketBeat's community ratings are surveys of what our community members think about Dendreon and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Dendreon stock can currently be purchased for approximately $0.13.
Consensus Ratings for Dendreon (NASDAQ:DNDN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Dendreon (NASDAQ:DNDN)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Dendreon (NASDAQ:DNDN)Earnings History by Quarter for Dendreon (NASDAQ DNDN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/10/2014||Q3||($0.10)||($0.14)||$78.72 million||$73.10 million||View||N/A|
|8/11/2014||($0.25)||($0.10)||$73.37 million||$82.16 million||View||N/A|
|5/8/2014||Q114||($0.28)||($0.24)||$69.19 million||$68.70 million||View||Listen|
|3/3/2014||Q413||($0.37)||($0.17)||$73.59 million||$74.80 million||View||Listen|
|11/12/2013||Q313||($0.42)||($0.44)||$76.60 million||$68.00 million||View||Listen|
|8/8/2013||Q2 2013||($0.42)||($0.45)||$75.61 million||$73.30 million||View||N/A|
|5/9/2013||Q1 2013||($0.47)||($0.48)||$80.15 million||$67.60 million||View||N/A|
|2/25/2013||Q4 2012||($0.56)||($0.26)||$82.88 million||$85.49 million||View||N/A|
|11/2/2012||Q312||($0.75)||($0.33)||$80.68 million||$78.00 million||View||N/A|
Earnings Estimates for Dendreon (NASDAQ:DNDN)
Current Year EPS Consensus Estimate: $-0.730 EPS
Next Year EPS Consensus Estimate: $-0.400 EPS
Dividend History for Dendreon (NASDAQ:DNDN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Dendreon (NASDAQ:DNDN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Dendreon (NASDAQ:DNDN)
Latest Headlines for Dendreon (NASDAQ:DNDN)
Dendreon (DNDN) Chart for Tuesday, September, 19, 2017